Healthy Adult SubjectsPhase 1NCT02691702

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

A Phase 1 study testing BIIB118 and Melatonin in people with Healthy Adult Subjects and Healthy Elderly Subjects, run by Biogen at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is the first clinical trial to evaluate ascending multiple oral doses in healthy adult and healthy elderly subjects to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BIIB118 Read more about this study

Who is it for?: Ages 18 to 85 yearsHealthy volunteers can take part
Conditions the study is for: Healthy Adult Subjects, Healthy Elderly Subjects
What is being tested?: BIIB118 and Melatonin
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 97 participants
Where: 2 sitesUnited States
Study dates: 28 Mar 2016to 12 Jan 2017
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 85 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years (Parts A and B) or 65 and 85 years (Part C), inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Female subjects of non-childbearing potential must meet at least one of the following criteria:
Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle-stimulating hormone (FSH) level confirming the post-menopausal state;
Have undergone a documented hysterectomy and/or bilateral oophorectomy;
Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Who cannot join

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer).
Screening supine blood pressure >= 140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), repeat per local standard operating procedures (SOP). If orthostatic changes are present and deemed to be clinically significant by the investigator, Subject can be excluded.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

QPS-MRA, LLC (Miami Research Associates)
South Miami, Florida, 33143
Qps-Mra, Llc
South Miami, Florida, 33143

Other trials in United States

About this study

Official title: A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects

Read the detailed description

This study was previously posted by Pfizer. In March, 2020, sponsorship of the trial was transferred to Biogen.

Conditions: Healthy Adult Subjects, Healthy Elderly Subjects
Being tested: BIIB118, Melatonin
Keywords: Multiple Ascending Dose Study, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Melatonin, Plasma, Dim Light Melatonin Onset

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

BIIB118Drug
Also called PF-05251749
Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
MelatoninDrug
Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.

Study groups in NCT02691702
Study group	Role	What they receive
Multiple Doses - Part A	Experimental	Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design Receives: Drug: BIIB118; Drug: Melatonin
Multiple Dose - Part B	Experimental	Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design Receives: Drug: BIIB118
Multiple Doses - Elderly	Experimental	Multiple ascending doses administered to elderly subjects Receives: Drug: BIIB118

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Measured: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Calmness
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Measured: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16- Mood
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Measured: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior"). The new onset and worsening of post-baseline suicidality for C-SSRS was reported.
Measured: Days 0, 7, 14, 16, and follow-up visit (28 calender days after the last dose of investigational product on Day 14).
Number of Participants With Treatment-Emergent Adverse Events (AEs) (All Causalities)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Treatment-Emergent Adverse Events (AEs) (Treatment Related)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin, PT international, ratio and fibrinogen, liver function(total bilirubin, direct bilirubin, aspartate, AST, Alanine, ALT, gamma GT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, phosphate, venous bicarbonate), clinical chemistry (glucose, creatinine kinase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine blood, urine urobilinogen, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine casts, urine bacteria), miscellaneous (absolute lymphocyte marker CD4, CD8, CD19)
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Absolute Values)
Number of participants with vital signs data of absolute values meeting categorical criteria was reported as following: (1) Supine systolic BP < 90 mmHg; (2) Supine Diastolic BP < 50 mmHg; (3) Supine Pulse Rate < 40 BPM ; (4) Supine Pulse Rate > 120 BPM.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Increases From Baseline)
Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum increase from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Decrease From Baseline)
Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum decrease from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Absolute Values)
Number of participants with ECG data of absolute values meeting categorical criteria was reported as following: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) >= 300 msec; Criterion B: maximum QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization)>= 140 msec; Criterion C: Maximum QT interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole)>= 500 msec; Criterion D: maximum QTC interval (QT interval corrected for heart rate) 450-<480 msec; Criterion E: maximum QTC interval 480-<500 msec; Criterion F: maximum QTC interval >=500 msec; Criterion G: maximum QTCF interval (QT interval corrected for heart rate using Fridericia's formula) 450 -< 480 msec; Criterion H: maximum QTCF interval 480 -< 500 msec; Criterion I: maximum QTCF interval >=500 msec.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Increase From Baseline)
Number of participants with ECG Data of increase from baseline meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)>=25/50%; Criterion B: maximum QRS complex increase from baseline PctChg >=50%; Criterion C: maximum QTC interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate) increase from baseline 30<=change<60 msec; Criterion D: maximum QTC interval increase from baseline change >=60 msec; Criterion E: maximum QTCF (Fridericia's correction) interval increase from baseline 30<=change<60; Criterion F: maximum QTCF interval increase from baseline change >=60 msec. Baseline was defined as the average of the triplicate measurements prior to dosing on Day 1.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With New/Intensified Physical Examination Findings
Physical examination included examination of ears, eyes, gastrointestinal, head, heart, lungs, lymph nodes, mouth, musculoskeletal, nose, skin. The number of participants with new-intensified physical examination findings were reported.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of Participants With New/Intensified Neurological Examination Findings
The number of participants with new-intensified neurological examination findings were reported.
Measured: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).

Secondary outcomes (15)

Maximum Plasma Concentration (Cmax) of PF-05251749 - Days 1, 7 and 14
Maximum plasma concentration (Cmax) of PF-05251749 was observed directly from data on Days 1, 7 and 14.
Measured: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Area Under the Concentration-Time Profile From Time 0 to Tau (AUCtau) of PF-05251749 - Days 1, 7 and 14.
AUCtau referred to the area under the curve from time 0 to time tau, the dosing interval, where tau equaled to 24 hours on Days 1, 7 and 14.
Measured: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Time at Which Cmax Occurred (Tmax) of PF-05251749 - Days 1, 7 and 14
Tmax of PF-05251749 was observed directly from data on Days 1, 7 and 14, as time of first occurrence.
Measured: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Apparent Clearance (CL/F) of PF-05251749 - Days 7 and 14
Apparent clearance was influenced by the fraction of the dose absorbed, which was measured by Dose/AUCtau.
Measured: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Minimum Concentration Observed (Cmin) of PF-05251749 - Days 7 and 14
Minimum concentration observed (Cmin) of PF-05251749 was observed directly from data on Days 7 and 14.
Measured: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Plasma Peak-to-trough Ratio (PTR) (Cmax/Cmin) of PF-05251749 - Days 7 and 14
Peak-to-through ratio (PTR) was the ratio of Cmax to Cmin, which was measured on Days 7 and 14.
Measured: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Observed Accumulation Ratio (Rac) of PF-05251749 -Days 7 and 14
Observed accumulation ratio (Rac) was calculated as AUCtau (Days 7 or 14) divided by AUCtau (Day 1).
Measured: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-05251749 - Days 7 and 14
Observed accumulation ratio for Cmax (Rac,Cmax) was calculated as: Cmax on Day 7 or 14 divided by Cmax on Day 1.
Measured: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Terminal Half-Life (t1/2) of PF-05251749 - Day 14
Terminal half-life (t1/2) was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.
Measured: Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Apparent Volume of Distribution (Vz/F) of PF-05251749 - Day 14
Apparent volume of distribution (Vz/F) was calculated by Dose/(AUCtau × kel) on Day 14.
Measured: Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Cumulative Amount of Drug Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau) of PF-05251749 - Day 14
Aetau was the cumulative amount of drug recovered unchanged in urine from time 0 to end of the dosing interval, which was calculated by sum of (urine concentration × volume of urine).
Measured: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Percentage of Dose Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau%) of PF-05251749 - Day 14
Aetau% was the percentage of dose recovered unchanged into urine from 0 to end of the dosing interval, which was calculated by 100 × Aetau/Dose.
Measured: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Renal Clearance (CLr) of PF-05251749 - Day 14
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), Aetau/AUCtau.
Measured: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 6
Dim Light Melatonin Onset (DLMO) was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points.
Measured: Day 0 (Baseline) and Day 6.
Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 15
DLMO was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points.
Measured: Day 0 (Baseline) and Day 15

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

28 Mar 201612 Jan 2017

First posted25 Feb 2016 (estimated)
Study start28 Mar 2016
Primary completion12 Jan 2017
Study completion12 Jan 2017

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Healthy Adult SubjectsStudies of the same condition, open and under way.
More trials run by BiogenThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 97 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02691702
Sponsor's protocol ID: B8001002
Other IDs: MAD
Status last verified: Feb 2021
First submitted: 22 Feb 2016
Last updated: 17 Feb 2021
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

Publications

Lin J, Gaudreault F, Johnson N, Lin Z, Nouri P, Goosen TC, Sawant-Basak A. Investigation of CYP3A induction by PF-05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response. Clin Transl Sci. 2022 Sep;15(9):2184-2194. doi: 10.1111/cts.13352. Epub 2022 Jul 2.
PubMed 35730131

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Acute Effects of High-Intensity Laser Therapy on Pain, Muscle Stiffness, and Grip Strength in Healthy Adults
Exercise-Induced Muscle Fatigue, Fatigue Recovery
RecruitingPhase 1
PET Imaging of the sigma1 Receptor in Healthy Adults
Healthy Control Subjects
RecruitingPhase 1
Phase Ia Study of MST-931 in Healthy Adult Subjects
Ankylosing Spondylitis (AS)
Active, not recruitingPhase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Pneumococcal Disease
RecruitingPhase 1
A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults
Healthy Subjects

All Healthy Adult Subjects trials

Study at a glance

From the registry record, last updated by the sponsor on 17 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects
ClinicalTrials.gov ID: NCT02691702
Acronym / sponsor ID: B8001002
Conditions: Healthy Adult Subjects, Healthy Elderly Subjects
Keywords: Multiple Ascending Dose Study, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Melatonin, Plasma, Dim Light Melatonin Onset
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 97 participants (actual)
Lead sponsor: BiogenIndustry (pharma, biotech, devices)
Study start: 28 Mar 2016 (actual)
Primary completion: 12 Jan 2017 (actual)
Study completion: 12 Jan 2017 (actual)
First posted: 25 Feb 2016 (estimated)
Results: Posted 15 Oct 2018

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This study was previously posted by Pfizer. In March, 2020, sponsorship of the trial was transferred to Biogen.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 3

Arm	Type	Receives
Multiple Doses - Part A	Experimental	Drug: BIIB118, Drug: MelatoninMultiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
Multiple Dose - Part B	Experimental	Drug: BIIB118Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
Multiple Doses - Elderly	Experimental	Drug: BIIB118Multiple ascending doses administered to elderly subjects

Who may qualify

Ages: 18 to 85 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (8 listed)

Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years (Parts A and B) or 65 and 85 years (Part C), inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Female subjects of non-childbearing potential must meet at least one of the following criteria:
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Key exclusion criteria (3 listed)

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer).
Screening supine blood pressure >= 140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), repeat per local standard operating procedures (SOP). If orthostatic changes are present and deemed to be clinically significant by the investigator, Subject can be excluded.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
BIIB118Also: PF-05251749Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks	Drug	Multiple Dose - Part B, Multiple Doses - Elderly, Multiple Doses - Part A
MelatoninPositive control used to assess the validity of DLMO as pharmacodynamic endpoint.	Drug	Multiple Doses - Part A

Primary outcome

Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness
Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Calmness
Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16- Mood
Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Days 0, 7, 14, 16, and follow-up visit (28 calender days after the last dose of investigational product on Day 14).
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior"). The new onset and worsening of post-baseline suicidality for C-SSRS was reported.
Number of Participants With Treatment-Emergent Adverse Events (AEs) (All Causalities)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Number of Participants With Treatment-Emergent Adverse Events (AEs) (Treatment Related)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin, PT international, ratio and fibrinogen, liver function(total bilirubin, direct bilirubin, aspartate, AST, Alanine, ALT, gamma GT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, phosphate, venous bicarbonate), clinical chemistry (glucose, creatinine kinase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine blood, urine urobilinogen, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine casts, urine bacteria), miscellaneous (absolute lymphocyte marker CD4, CD8, CD19)
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Absolute Values)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of participants with vital signs data of absolute values meeting categorical criteria was reported as following: (1) Supine systolic BP < 90 mmHg; (2) Supine Diastolic BP < 50 mmHg; (3) Supine Pulse Rate < 40 BPM ; (4) Supine Pulse Rate > 120 BPM.
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Increases From Baseline)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum increase from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing.
Number of Participants With Vital Signs Data Meeting Categorical Criteria (Decrease From Baseline)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum decrease from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing.
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Absolute Values)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of participants with ECG data of absolute values meeting categorical criteria was reported as following: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) >= 300 msec; Criterion B: maximum QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization)>= 140 msec; Criterion C: Maximum QT interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole)>= 500 msec; Criterion D: maximum QTC interval (QT interval corrected for heart rate) 450-<480 msec; Criterion E: maximum QTC interval 480-<500 msec; Criterion F: maximum QTC interval >=500 msec; Criterion G: maximum QTCF interval (QT interval corrected for heart rate using Fridericia's formula) 450 -< 480 msec; Criterion H: maximum QTCF interval 480 -< 500 msec; Criterion I: maximum QTCF interval >=500 msec.
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Increase From Baseline)
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Number of participants with ECG Data of increase from baseline meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)>=25/50%; Criterion B: maximum QRS complex increase from baseline PctChg >=50%; Criterion C: maximum QTC interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate) increase from baseline 30<=change<60 msec; Criterion D: maximum QTC interval increase from baseline change >=60 msec; Criterion E: maximum QTCF (Fridericia's correction) interval increase from baseline 30<=change<60; Criterion F: maximum QTCF interval increase from baseline change >=60 msec. Baseline was defined as the average of the triplicate measurements prior to dosing on Day 1.
Number of Participants With New/Intensified Physical Examination Findings
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Physical examination included examination of ears, eyes, gastrointestinal, head, heart, lungs, lymph nodes, mouth, musculoskeletal, nose, skin. The number of participants with new-intensified physical examination findings were reported.
Number of Participants With New/Intensified Neurological Examination Findings
Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
The number of participants with new-intensified neurological examination findings were reported.

15 secondary outcomes

Maximum Plasma Concentration (Cmax) of PF-05251749 - Days 1, 7 and 14
Time frame: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Area Under the Concentration-Time Profile From Time 0 to Tau (AUCtau) of PF-05251749 - Days 1, 7 and 14.
Time frame: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Time at Which Cmax Occurred (Tmax) of PF-05251749 - Days 1, 7 and 14
Time frame: Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Apparent Clearance (CL/F) of PF-05251749 - Days 7 and 14
Time frame: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Minimum Concentration Observed (Cmin) of PF-05251749 - Days 7 and 14
Time frame: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Plasma Peak-to-trough Ratio (PTR) (Cmax/Cmin) of PF-05251749 - Days 7 and 14
Time frame: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Observed Accumulation Ratio (Rac) of PF-05251749 -Days 7 and 14
Time frame: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-05251749 - Days 7 and 14
Time frame: Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Terminal Half-Life (t1/2) of PF-05251749 - Day 14
Time frame: Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Apparent Volume of Distribution (Vz/F) of PF-05251749 - Day 14
Time frame: Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h).
Cumulative Amount of Drug Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau) of PF-05251749 - Day 14
Time frame: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Percentage of Dose Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau%) of PF-05251749 - Day 14
Time frame: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Renal Clearance (CLr) of PF-05251749 - Day 14
Time frame: Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h).
Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 6
Time frame: Day 0 (Baseline) and Day 6.
Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 15
Time frame: Day 0 (Baseline) and Day 15

Results and safety

Results posted to the registry on 15 Oct 2018, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo (Part A)	10	8
Melatonin 0.5 mg PM (Part A)	11	10
PF-05251749 50 mg AM (Part A)	8	7
PF-05251749 100 mg AM (Part A)	8	8
PF-05251749 200 mg AM (Part A)	8	8
PF-05251749 400 mg AM (Part A)	8	5
PF-05251749 750 mg AM (Part A)	8	5
Placebo (Part B)	12	12
PF-05251749 50 mg PM (Part B)	8	6
PF-05251749 200 mg PM (Part B)	8	6
PF-05251749 500 mg PM (Part B)	8	6

Primary outcome: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness

Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).. Mean (Standard Deviation). Unit: Units on a scale

Measure	Placebo (Part A) n = 10	Melatonin 0.5 mg PM (Part A) n = 11	PF-05251749 50 mg AM (Part A) n = 8	PF-05251749 100 mg AM (Part A) n = 8	PF-05251749 200 mg AM (Part A) n = 8	PF-05251749 400 mg AM (Part A) n = 8	PF-05251749 750 mg AM (Part A) n = 8	Placebo (Part B) n = 12	PF-05251749 50 mg PM (Part B) n = 8	PF-05251749 200 mg PM (Part B) n = 8	PF-05251749 500 mg PM (Part B) n = 8
Day 1 (2h)	2.16 (7.405)	7.50 (8.043)	6.71 (12.314)	3.50 (10.071)	4.58 (9.472)	4.05 (6.038)	1.49 (11.514)	-0.08 (6.382)	-2.83 (7.314)	-6.04 (10.085)	-1.93 (7.953)
Day 4 (1.5h)	-0.61 (14.480)	5.88 (8.943)	6.46 (11.092)	6.51 (11.209)	3.48 (12.533)	6.23 (8.043)	-14.45 (17.182)	-0.46 (7.105)	-0.25 (6.349)	0.65 (8.135)	-3.00 (5.143)
Day 7 (0h)	-4.00 (22.474)	3.76 (11.243)	2.21 (12.305)	6.96 (9.630)	3.39 (12.541)	6.54 (12.898)	-2.14 (9.437)	1.23 (6.356)	-0.50 (6.514)	0.23 (5.771)	-0.79 (5.109)
Day 7 (2h)	-2.87 (21.022)	-0.63 (20.162)	4.03 (14.212)	7.54 (9.519)	2.76 (6.221)	8.04 (11.784)	-10.92 (15.343)	1.57 (5.817)	-1.25 (6.743)	-3.00 (11.517)	-4.93 (9.924)
Day 10 (1.5h)	-2.97 (20.833)	4.76 (13.174)	5.83 (12.879)	6.20 (6.462)	4.83 (7.288)	7.51 (10.848)	-9.08 (21.071)	1.31 (5.667)	-0.09 (7.507)	-0.82 (7.100)	-0.53 (6.265)
Day 14 (0h)	1.19 (16.566)	4.97 (10.320)	5.68 (12.631)	1.50 (5.458)	2.96 (10.782)	8.30 (11.045)	5.12 (9.507)	1.43 (5.532)	-1.93 (9.227)	0.18 (10.212)	-0.89 (8.264)
Day 14 (2h)	-0.53 (17.945)	7.18 (11.543)	6.03 (13.385)	1.75 (14.316)	4.15 (11.839)	6.16 (11.063)	0.42 (5.971)	2.83 (5.437)	0.28 (3.998)	2.25 (5.623)	-3.33 (8.503)
Day 15 (0h)	1.55 (15.940)	7.38 (10.892)	3.51 (16.583)	9.13 (10.092)	2.13 (14.382)	8.57 (12.525)	9.20 (8.385)	1.62 (5.057)	1.07 (4.223)	3.15 (3.971)	-1.93 (6.736)

Population analysed: The safety analysis set included all participants who received at least 1 dose of study treatment.

Primary outcome: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Calmness

Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).. Mean (Standard Deviation). Unit: Units on a scale

Measure	Placebo (Part A) n = 10	Melatonin 0.5 mg PM (Part A) n = 11	PF-05251749 50 mg AM (Part A) n = 8	PF-05251749 100 mg AM (Part A) n = 8	PF-05251749 200 mg AM (Part A) n = 8	PF-05251749 400 mg AM (Part A) n = 8	PF-05251749 750 mg AM (Part A) n = 8	Placebo (Part B) n = 12	PF-05251749 50 mg PM (Part B) n = 8	PF-05251749 200 mg PM (Part B) n = 8	PF-05251749 500 mg PM (Part B) n = 8
Day 1 (2h)	0.70 (7.997)	1.45 (3.940)	3.56 (16.668)	13.88 (20.662)	1.56 (1.522)	2.25 (5.175)	1.81 (9.509)	-0.38 (2.630)	-2.06 (6.032)	-15.31 (20.114)	-0.56 (3.774)
Day 4 (1.5h)	1.00 (10.808)	4.00 (12.092)	7.50 (24.391)	16.13 (22.448)	-1.75 (8.302)	1.50 (1.732)	-11.25 (18.030)	1.25 (8.081)	-1.75 (4.652)	-5.83 (10.405)	1.19 (5.035)
Day 7 (0h)	-3.17 (20.352)	-3.85 (11.255)	8.63 (24.013)	13.44 (21.089)	1.06 (2.129)	0.50 (3.948)	-12.10 (25.289)	1.08 (7.902)	-5.19 (14.258)	-4.00 (4.950)	3.36 (10.351)
Day 7 (2h)	-2.22 (20.935)	0.40 (10.572)	7.56 (24.693)	14.44 (20.859)	1.44 (1.348)	2.14 (2.593)	-13.30 (26.537)	1.54 (8.349)	-2.31 (6.954)	-8.58 (9.881)	-1.21 (12.419)
Day 10 (1.5h)

Primary outcome: Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16- Mood

Time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).. Mean (Standard Deviation). Unit: Units on a scale

Measure	Placebo (Part A) n = 10	Melatonin 0.5 mg PM (Part A) n = 11	PF-05251749 50 mg AM (Part A) n = 8	PF-05251749 100 mg AM (Part A) n = 8	PF-05251749 200 mg AM (Part A) n = 8	PF-05251749 400 mg AM (Part A) n = 8	PF-05251749 750 mg AM (Part A) n = 8	Placebo (Part B) n = 12	PF-05251749 50 mg PM (Part B) n = 8	PF-05251749 200 mg PM (Part B) n = 8	PF-05251749 500 mg PM (Part B) n = 8
Day 1 (2h)	1.16 (4.480)	5.16 (15.927)	2.20 (12.642)	2.03 (5.579)	5.55 (13.357)	3.25 (7.391)	0.50 (8.384)	0.32 (5.402)	-1.43 (5.432)	-7.80 (11.921)	-2.85 (10.557)
Day 4 (1.5h)	-1.42 (13.299)	2.78 (15.744)	1.85 (11.244)	2.30 (12.752)	6.84 (12.834)	5.23 (7.530)	-12.73 (13.168)	1.25 (5.218)	-3.13 (8.269)	-8.60 (12.057)	-1.73 (3.798)
Day 7 (0h)	-3.73 (17.841)	-1.86 (12.644)	0.93 (12.440)	6.20 (9.953)	7.30 (13.407)	5.83 (10.032)	-6.68 (11.595)	-0.45 (7.295)	-0.38 (4.313)	-4.90 (6.395)	-3.06 (3.878)
Day 7 (2h)	-3.00 (17.138)	3.30 (14.328)	6.65 (11.230)	3.83 (8.980)	6.30 (8.661)	5.83 (9.082)	-10.84 (11.344)	1.32 (5.811)	-2.83 (7.719)	-2.87 (3.110)	-10.00 (16.401)
Day 10 (1.5h)	-3.84 (18.444)

Primary outcome: Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS)

Time frame: Days 0, 7, 14, 16, and follow-up visit (28 calender days after the last dose of investigational product on Day 14).. Number. Unit: Participants

Measure	Placebo (Part A) n = 10	Melatonin 0.5 mg PM (Part A) n = 11	PF-05251749 50 mg AM (Part A) n = 8	PF-05251749 100 mg AM (Part A) n = 8	PF-05251749 200 mg AM (Part A) n = 8	PF-05251749 400 mg AM (Part A) n = 8	PF-05251749 750 mg AM (Part A) n = 8	Placebo (Part B) n = 12	PF-05251749 50 mg PM (Part B) n = 8	PF-05251749 200 mg PM (Part B) n = 8	PF-05251749 500 mg PM (Part B) n = 8
Day 0	0	0	0	0	0	0	0	0	0	0	0
Day 7	0	0	0	0	0	0	0	0	0	0	0
Day 14	0	0	0	0	0	0	0	0	0	0	0
Day 16	0	0	0	0	0	0	0	0	0	0	0
Follow-up	0	0	0	0	0	0	0	0	0	0	0

Population analysed: The safety analysis set included all participants who received at least 1 dose of study treatment.

15 secondary outcomes are reported in the full results.

Adverse events

Time frame: Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo (Part A)	0 of 10 (0%)	4 of 10 (40%)	0 of 10
Melatonin 0.5 mg PM (Part A)	0 of 11 (0%)	3 of 11 (27.3%)	0 of 11
PF-05251749 50 mg AM (Part A)	0 of 8 (0%)	3 of 8 (37.5%)	0 of 8
PF-05251749 100 mg AM (Part A)	0 of 8 (0%)	1 of 8 (12.5%)	0 of 8
PF-05251749 200 mg AM (Part A)	0 of 8 (0%)	5 of 8 (62.5%)	0 of 8
PF-05251749 400 mg AM (Part A)	0 of 8 (0%)	7 of 8 (87.5%)	0 of 8
PF-05251749 750 mg AM (Part A)	0 of 8 (0%)	7 of 8 (87.5%)	0 of 8
Placebo (Part B)	0 of 12 (0%)	3 of 12 (25%)	0 of 12
PF-05251749 50 mg PM (Part B)	1 of 8 (12.5%)	4 of 8 (50%)	0 of 8
PF-05251749 200 mg PM (Part B)	0 of 8 (0%)	2 of 8 (25%)	0 of 8
PF-05251749 500 mg PM (Part B)	0 of 8 (0%)	8 of 8 (100%)	0 of 8

Limitations and caveats (from the sponsor): From Parts A and B, it was deemed that safety, tolerability, PK and PD objectives were met, so Part C was not conducted. Because of limited saliva sampling duration (06:00 PM to 12:00 AM), DLMO observation(s) beyond midnight could not be quantified.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2021.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 35730131Lin J, Gaudreault F, Johnson N, Lin Z, Nouri P, Goosen TC, Sawant-Basak A. Investigation of CYP3A induction by PF-05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response. Clin Transl Sci. 2022 Sep;15(9):2184-2194. doi: 10.1111/cts.13352. Epub 2022 Jul 2.
To obtain contact information for a study center near you, click here.Link provided by the sponsor.

Related trials for Healthy Adult Subjects

Not yet recruiting
Acute Effects of High-Intensity Laser Therapy on Pain, Muscle Stiffness, and Grip Strength in Healthy Adults
Exercise-Induced Muscle Fatigue, Fatigue Recovery
RecruitingPhase 1
PET Imaging of the sigma1 Receptor in Healthy Adults
Healthy Control Subjects
RecruitingPhase 1
Phase Ia Study of MST-931 in Healthy Adult Subjects
Ankylosing Spondylitis (AS)
Active, not recruitingPhase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Pneumococcal Disease
RecruitingPhase 1
A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults
Healthy Subjects

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Medical Director study director

Biogen

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing BIIB118 and Melatonin in people with Healthy Adult Subjects and Healthy Elderly Subjects, run by Biogen at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Oct 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness (time frame: Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h).). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02691702, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2021.